Description:
The purpose of this study is to determine the safety of TAS-119 and determine the most
appropriate dose in combination with Paclitaxel for subsequent studies in patients with
advanced solid tumors.
TAS-119 is a novel, selective Aurora A kinase inhibitor, which has previously been
demonstrated to enhance the activity of paclitaxel in preclinical studies
Title
- Brief Title: Dose-escalating, Safety, Tolerability and PK Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
- Official Title: A Phase 1, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-119 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Clinical Trial IDs
- ORG STUDY ID:
TO-TAS-119-101
- NCT ID:
NCT02134067
Conditions
Interventions
| Drug | Synonyms | Arms |
|---|
| TAS-119 | | TAS-119 |
| Paclitaxel | Taxol | TAS-119 |
Purpose
The purpose of this study is to determine the safety of TAS-119 and determine the most
appropriate dose in combination with Paclitaxel for subsequent studies in patients with
advanced solid tumors.
TAS-119 is a novel, selective Aurora A kinase inhibitor, which has previously been
demonstrated to enhance the activity of paclitaxel in preclinical studies
Detailed Description
Background and rationale for study:
In nonclinical pharmacology studies TAS-119 significantly enhanced the antitumor activity of
the microtubule stabilizer paclitaxel and TAS-119 is being developed for use in combination
with paclitaxel.
TAS-119 selectively inhibits the kinase inhibitor Aurora A. AurA regulates cell division by
controlling the transition from G2 to M phase. Overexpression of AurA is associated with
resistance to taxanes.
The study will be conducted in two sequential phases:
Dose Escalation Phase with the purpose to determine the maximum tolerated dose and the
recommended Phase 2 dose of TAS-119 given in combination with paclitaxel
An Expansion Phase in which additional patients will be enrolled to further evaluate the
safety and preliminary efficacy of the recommended Phase 2 dose of TAS-119 in combination
with paclitaxel, during which a subgroup of patients will be evaluated for DDI between
paclitaxel and TAS-119 via PK assessment.
Trial Arms
| Name | Type | Description | Interventions |
|---|
| TAS-119 | Experimental | TAS-119 tablets, oral, dose-escalating, 28-day cycle.
Paclitaxel (90mg/m2) is administered IV in combination with TAS-119 in each of the arms. | |
Eligibility Criteria
Inclusion Criteria:
1. Is a male or female ≥ 18 years of age, that has provided written informed consent.
2. Has histologically or cytologically confirmed advanced, unresectable metastatic solid
tumor(s) for which the patients have no available therapy likely to provide clinical
benefit, or for which paclitaxel is considered a standard of care.
3. Has adequate organ function as defined by the following criteria:
- Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤
3.0 × upper limit of normal (ULN); if liver function abnormalities are due to
underlying liver metastasis, AST (SGOT) and ALT (SGPT) ≤ 5 × ULN.
- Total serum bilirubin ≤ 1.5 × ULN.
- Absolute neutrophil count ≥ 1,500/mm3 (excluding measurements obtained within 7
days after administration of granulocyte colony-stimulating factor [G-CSF]).
- Platelet count ≥ 100,000/mm3 (IU: ≥ 100 × 109/L) (excluding measurements obtained
within 7 days after a transfusion of platelets).
- Hemoglobin ≥ 9.0 g/dL
- Total serum creatinine ≤ 1.5 × ULN
- Serum albumin ≥ 3.0 mg/dL.
Exclusion Criteria:
1. Previous inability to tolerate any dose of paclitaxel (i.e., the subject required a
paclitaxel dose reduction or discontinuation).
2. Has received any treatments prohibited in this trial within specified time frames
3. Has a serious illness or medical condition(s) that would affect safety or tolerability
of the study treatments
4. Has history of Grade 2 or greater peripheral neuropathy during the 3 months prior to
enrollment.
5. Has known hypersensitivity to TAS-119 or its components.
6. Has known hypersensitivity to Cremophor® EL, paclitaxel or its components.
7. Is a pregnant or lactating female.
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
Primary Outcome Measures
| Measure: | Safety and tolerability of TAS-119 in combination with paclitaxel |
| Time Frame: | Safety monitoring will begin at the time of the first dose of TAS-119, and will continue until all patients are discontinued from treatment or until 12 months from the last patient enrolled (up to 3 years). |
| Safety Issue: | |
| Description: | Standard safety monitoring and grading using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 will be used.
The safety and tolerability of TAS-119 will be evaluated by the number and severity of adverse events, vital signs, physical exam, and clinical laboratory assessments. |
Secondary Outcome Measures
| Measure: | Overall response according to RECIST guidelines (version 1.1, 2009) |
| Time Frame: | Computed tomography (CT) scans for tumor imaging will be performed at the end of every 2 treatment cycles (8 weeks) and an average of 4 cycles (16 weeks) |
| Safety Issue: | |
| Description: | The determination of antitumor efficacy will be based on objective tumor assessments made by the investigator according to RECIST guidelines (version 1.1, 2009). |
Details
| Phase: | Phase 1 |
| Primary Purpose: | Interventional |
| Overall Status: | Terminated |
| Lead Sponsor: | Taiho Oncology, Inc. |
Trial Keywords
- advanced solid tumors
- tumor
- Dose Escalation
- TAS-119
- Taxane
- Paclitaxel
- Aurora A kinase inhibitor
- AurA
Last Updated
February 21, 2020
